These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 28078583)
1. Generation and Application of Bioluminescent CD95 Ligand Fusion Proteins. Lang I; Kums J; Wajant H Methods Mol Biol; 2017; 1557():63-77. PubMed ID: 28078583 [TBL] [Abstract][Full Text] [Related]
2. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts. Lang I; Fick A; Schäfer V; Giner T; Siegmund D; Wajant H J Biol Chem; 2012 Jul; 287(28):24026-42. PubMed ID: 22645131 [TBL] [Abstract][Full Text] [Related]
3. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. Assohou-Luty C; Gerspach J; Siegmund D; Müller N; Huard B; Tiegs G; Pfizenmaier K; Wajant H J Mol Med (Berl); 2006 Sep; 84(9):785-97. PubMed ID: 16924474 [TBL] [Abstract][Full Text] [Related]
4. CD95 Stimulation with CD95L and DISC Analysis. Le Gallo M; Legembre P Methods Mol Biol; 2017; 1557():11-18. PubMed ID: 28078578 [TBL] [Abstract][Full Text] [Related]
5. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884 [TBL] [Abstract][Full Text] [Related]
6. Fluorescence resonance energy transfer analysis of proapoptotic CD95-EGF receptor interactions in Huh7 cells. Eberle A; Reinehr R; Becker S; Häussinger D Hepatology; 2005 Feb; 41(2):315-26. PubMed ID: 15660394 [TBL] [Abstract][Full Text] [Related]
7. CD95 ligand: lethal weapon against malignant glioma? Weller M; Kleihues P; Dichgans J; Ohgaki H Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287 [TBL] [Abstract][Full Text] [Related]
8. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection. Cossarizza A; Stent G; Mussini C; Paganelli R; Borghi V; Nuzzo C; Pinti M; Pedrazzi J; Benatti F; Esposito R; Røsok B; Nagata S; Vella S; Franceschi C; De Rienzo B AIDS; 2000 Mar; 14(4):345-55. PubMed ID: 10770536 [TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis. Watson GA; Naran S; Zhang X; Stang MT; Queiroz de Oliveira PE; Hughes SJ Neoplasia; 2011 Mar; 13(3):198-205. PubMed ID: 21390183 [TBL] [Abstract][Full Text] [Related]
10. Production of the Non-apoptotic Metalloprotease-Cleaved CD95L and Its Cytotoxic Recombinant Counterpart Designed Ig-CD95L. Lepvrier E; Martin S; Collet B Methods Mol Biol; 2017; 1557():1-10. PubMed ID: 28078577 [TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models. Quijano-Rubio C; Silginer M; Weller M J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258 [TBL] [Abstract][Full Text] [Related]
12. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand. Ng CS; Lo ST; Chan JK Hum Pathol; 1999 Jan; 30(1):48-53. PubMed ID: 9923926 [TBL] [Abstract][Full Text] [Related]
13. Differential down-regulation of CD95 or CD95L in chronically HIV-infected cells of monocytic or lymphocytic origin: cellular studies and molecular analysis by quantitative competitive RT-PCR. Pinti M; Pedrazzi J; Benatti F; Sorrentino V; Nuzzo C; Cavazzuti V; Biswas P; Petrusca DN; Mussini C; De Rienzo B; Cossarizza A FEBS Lett; 1999 Sep; 458(2):209-14. PubMed ID: 10481067 [TBL] [Abstract][Full Text] [Related]
14. Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR. Pinti M; Nasi M; Moretti L; Mussini C; Petrusca D; Esposito R; Cossarizza A Ann N Y Acad Sci; 2000; 926():46-51. PubMed ID: 11193040 [TBL] [Abstract][Full Text] [Related]
15. CD95-tyrosine nitration inhibits hyperosmotic and CD95 ligand-induced CD95 activation in rat hepatocytes. Reinehr R; Görg B; Höngen A; Häussinger D J Biol Chem; 2004 Mar; 279(11):10364-73. PubMed ID: 14679192 [TBL] [Abstract][Full Text] [Related]
16. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. Bellone G; Smirne C; Carbone A; Mareschi K; Dughera L; Farina EC; Alabiso O; Valente G; Emanuelli G; Rodeck U Clin Cancer Res; 2000 Jun; 6(6):2448-55. PubMed ID: 10873098 [TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of cells with combined apoptosis and proliferation markers in thyroid tissue specimens from patients with cancer, adenoma, and autoimmune diseases. Kazakov SP; Zabotina TN; Korotkova OV; Dzabarov AK; Kazantseva IA Bull Exp Biol Med; 2011 Feb; 150(4):453-8. PubMed ID: 22268042 [TBL] [Abstract][Full Text] [Related]
18. Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death. Stohl W; Xu D; Starling GC; Casali P; Kiener PA Cell Immunol; 2000 Jul; 203(1):1-11. PubMed ID: 10915556 [TBL] [Abstract][Full Text] [Related]
19. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Moers C; Warskulat U; Müschen M; Even J; Niederacher D; Josien R; Koldovsky U; Beckmann MW; Häussinger D Int J Cancer; 1999 Feb; 80(4):564-72. PubMed ID: 9935158 [TBL] [Abstract][Full Text] [Related]